Nuvation Bio (NYSE:NUVB) Shares Gap Down - Time to Sell?

Nuvation Bio Inc. (NYSE:NUVB - Get Free Report)'s stock price gapped down prior to trading on Monday . The stock had previously closed at $1.73, but opened at $1.66. Nuvation Bio shares last traded at $1.79, with a volume of 3,097,573 shares traded.

Wall Street Analysts Forecast Growth

NUVB has been the topic of a number of recent research reports. HC Wainwright cut their price target on shares of Nuvation Bio from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Monday, March 10th. JMP Securities reiterated a "market outperform" rating and issued a $6.00 target price on shares of Nuvation Bio in a research note on Monday, June 2nd. Citizens Jmp started coverage on shares of Nuvation Bio in a report on Wednesday, April 23rd. They issued a "mkt outperform" rating and a $6.00 target price on the stock. Wedbush restated an "outperform" rating and set a $5.00 price target on shares of Nuvation Bio in a report on Wednesday, June 11th. Finally, Citigroup assumed coverage on Nuvation Bio in a research report on Wednesday, April 23rd. They issued an "outperform" rating on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $7.83.

Nuvation Bio Stock Performance

The company has a 50-day moving average of $2.15 and a 200 day moving average of $2.29. The firm has a market cap of $614.17 million, a P/E ratio of -0.83 and a beta of 1.37.

Nuvation Bio (NYSE:NUVB - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.16). The company had revenue of $3.08 million for the quarter, compared to the consensus estimate of $0.42 million. Sell-side analysts anticipate that Nuvation Bio Inc. will post -0.36 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO David Hung acquired 200,000 shares of the stock in a transaction that occurred on Friday, April 4th. The stock was purchased at an average cost of $1.66 per share, for a total transaction of $332,000.00. Following the completion of the transaction, the chief executive officer now directly owns 58,481,054 shares in the company, valued at $97,078,549.64. This trade represents a 0.34% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Dongfang Liu sold 20,000 shares of the firm's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $2.50, for a total transaction of $50,000.00. Following the completion of the transaction, the insider now directly owns 12,000 shares in the company, valued at $30,000. This trade represents a 62.50% decrease in their position. The disclosure for this sale can be found here. Insiders own 29.93% of the company's stock.

Institutional Investors Weigh In On Nuvation Bio

Several institutional investors have recently modified their holdings of NUVB. Wealth Enhancement Advisory Services LLC bought a new position in Nuvation Bio in the fourth quarter valued at approximately $27,000. Forum Financial Management LP bought a new position in shares of Nuvation Bio in the 4th quarter worth $29,000. Cerity Partners LLC bought a new position in shares of Nuvation Bio in the 4th quarter worth $31,000. Firethorn Wealth Partners LLC acquired a new stake in shares of Nuvation Bio during the first quarter worth $35,000. Finally, Russell Investments Group Ltd. increased its holdings in Nuvation Bio by 15,183.7% in the fourth quarter. Russell Investments Group Ltd. now owns 15,895 shares of the company's stock valued at $42,000 after purchasing an additional 15,791 shares during the last quarter. Institutional investors and hedge funds own 61.67% of the company's stock.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.